-
Zealand Pharma – Transactions related to share buy-back program (week 27, 2026)
Company announcement No. 31 / 2026 Zealand Pharma – Transactions related to share buy-back program (week 27, 2026) Copenhagen, Denmark, July 6, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the…
-
World’s First International Patient Begins Treatment with Newly Approved Solid Tumor CAR-T Therapy at Jiahui International Cancer Center
SHANGHAI, July 6, 2026 /PRNewswire/ — Jiahui International Cancer Center (JICC) has welcomed the world’s first international patient to begin treatment with Satri-cel, the world’s first approved CAR-T therapy for a solid tumor, marking a historic milestone in expanding global access to China’s latest oncology innovations. Josh, a 59-year-old patient from New Zealand with advanced…
-
A ‘founding father of fitness’ – Les Mills Snr 1934 – 2026
AUCKLAND, New Zealand, June 29, 2026 /PRNewswire/ — We pay heartfelt tribute to our founder, Les Mills Snr, who passed away peacefully today, aged 91. A Kiwi icon, Les blazed a trail in sport, business, politics and life. Together with his wife Colleen, he created a fitness dynasty, first through the Les Mills New Zealand (LMNZ)…
-
Millionaires on the Move: Winners, Losers, and the Global Competition for Wealth in 2026
LONDON, June 16, 2026 /PRNewswire/ — Singapore, Italy, Switzerland, Greece, Hong Kong, and New Zealand are emerging as some of the most attractive destinations for internationally mobile wealth in 2026 , while the United Kingdom, Germany, France, Norway, and South Korea are facing growing competitiveness pressures as tax reforms, fiscal uncertainty, and policy shifts prompt…
-
Zealand Pharma – Transactions related to share buy-back program (week 22, 2026)
Company announcement No. 20 / 2026 Zealand Pharma – Transactions related to share buy-back program (week 22, 2026) Copenhagen, Denmark, June 1, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
